A First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System

Inclusion Criteria: * All patients participating in this clinical trial must meet the following criteria: 1. Age of 18-75， males or non pregnancy females; 2. Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, post-infarct angina or silent ischemia) suitable for elective PCI; 3. One target lesion, and target lesion can be completely covered by a single stent; 4. Target lesion length ≤ 18 mm, target lesion diameter between 3.0 mm to 3.5 mm (visual); 5. Visual assessment of target lesion stenosis ≥70%, TIMI blood flow≥ 1; 6. Subject who understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up. Exclusion Criteria: * Patients will be excluded if any of the following conditions apply: General: 1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal; 2. Implantation of stent in target vessel within 1 year , patients with planned intervention again within six months; 3. Patients who performed coronary artery bypass (coronary artery bypass grafting); 4. Patients with contraindications for coronary artery bypass graft surgery; 5. Severe heart failure (NYHA class III and above) or left ventricular ejection fraction\<40% (ultrasonic or left ventricular angiography); 6. Preoperative renal function: serum creatinine \> 2.0 mg/dl or 177 mu mol/L; receiving hemodialysis; 7. Patients have ischemic stroke half a year before implantation, patients have transient ischemic attack 3 months before implantation, patients have high coagulation tendency judged by investigator or laboratory examination; 8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage, contraindications on antiplatelet agents and anticoagulant therapy; patients would not allow to undergoing antithrombotic therapy; 9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer, rapamycin and metal allergies; 10. Patients who have a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc; 11. The patient's life expectancy is less than 12 months; 12. Patient participated in other drug or medical device study and does not meet the primary study endpoint in clinical trials time frame; 13. Poor compliance and patients unable to complete the study in accordance with the requirements; 14. Patient with heart transplant; 15. The unstable arrhythmia, such as high risk ventricular extra systole and ventricular tachycardia; 16. Cancer needs chemotherapy; 17. Patients of immune suppression, autoimmune diseases, planned or undergoing immunosuppressive therapy; 18. Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc; 19. With six months for elective surgery requires stop using aspirin and clopidogrel; 20. Blood test prompted platelet count \< 100 x 109/L, or \> 700 x 109/L, white blood cells \< 3 x 109/L, or abnormal liver function (ALT、AST 3 times greater than normal range); 21. Patients with diffuse peripheral vascular disease; cannot use 6F catheter; 22. Patients with valvular surgery in the past. Exclusion criteria by angiography: 1. Chronic total occlusion (TIMI blood flow=0 before implantation) , left main coronary artery lesion, ostial lesion, multiple vessel lesion, branch lesion and bridge lesion which branch vessel diameter ≥ 2.0 mm (if the ostium of branch vessel stenosis \>40% or needs balloon predilation); visible thrombus in target vessels; 2. Severe calcified lesions and distorted disease which unable to predilation, lesion not suitable for stent delivery and expansion; 3. In-stent restenosis; 4. Myocardial bridge is involved in target lesion; 5. In order to reach the target lesion, study stent has to go through the previous implanted stent; 6. Predilation balloon can't expand completely in target lesion site, judgment standard for fully expansion as below, patients are excluded when do not meet any item: A. DS% \< 40%（visual），highly recommend DS% ≤20% B. TIMI blood flow= class 3（visual） C. No angiography complications (e.g., distal embolization, lateral branch closed) D. No interlining level NHLBI type D - F E. No continuous chest pain (\> 5 minutes), and F. No lower or higher ST segment \>5 minutes.